ArticleBioactive materials2027
Y-RBCEVs accelerate fracture repair through osteogenesis and VCAN-mediated CD44/PI3K/AKT-dependent macrophage polarization.
Article in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the effects of young human red blood cell-derived extracellular vesicles (Y-RBCEVs) on fracture healing. Methods: Associations of RBC-related indicators with bone mineral density and mortality in fracture populations were analyzed using NHANES data (1999-2020). A murine femoral fracture model was established to investigate RBC transfusion effects. Y-RBCEVs and O-RBCEVs were isolated to examine their effects on osteogenic differentiation and BMM polarization in vitro. In vivo distribution was assessed by IVIS, and therapeutic efficacy was evaluated in fracture mice. Proteomic sequencing identified differentially expressed proteins between Y-RBCEVs and O-RBCEVs, and key protein function was investigated by transcriptomic analysis and in vitro validation. Results: The observational study revealed associations between RBC count and bone mineral density with fracture populations mortality. RBC transfusion modulated the expression of osteogenic and M2 macrophage polarization-related genes. In vitro, RBCEVs were efficiently internalized by BMSCs and BMMs, with Y-RBCEVs enhancing osteogenic activity in BMSCs and promoting M2 macrophage polarization, thereby partially restoring osteogenesis impaired by inflammatory conditions. In vivo, Y-RBCEVs accumulated at fracture sites and enhanced bone regeneration without detectable toxicity, accompanied by increased OCN and CD206 expression. Proteomic analysis identified VCAN as one of the potential functional cargos. Mechanistically, Y-RBCEV-derived VCAN interacted with CD44 on macrophages and was associated with activation of the PI3K/AKT pathway, contributing to M2 polarization. Conclusion: Y-RBCEVs enhance fracture repair by modulating osteogenesis and macrophage polarization, with VCAN-associated CD44/PI3K/AKT signaling contributing to their osteo-immunomodulatory effects. These findings highlight RBCEVs as a potential therapeutic strategy for bone regeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.